Form 4 for VNDA Vanda Pharmaceuticals Inc.
Accepted 2026-04-24 16:36:42 ET · period of report 2026-04-22 · accession 0002130896-26-000008 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-24 16:36 | 2026-04-22 | VNDA | Duncan Charles Cliff | Dir | A - Grant | $0.00 | +57.1K | 57.1K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-04-22 | A | A | 57,101 | $0.00 | 57,101 | D | — | — | (F1) Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on April 22, 2027, provided the Reporting Person has provided continuous service to the Issuer through each annual vesting date. |